Group includes leading experts in multiple disciplines including immunology, liver diseases, protein engineering, antibody drug conjugates and platform innovation
Tharimmune Forms Scientific Advisory Board To Drive Clinical-Stage Lead In Chronic Liver Disease And Early-Stage Tunable Knob Domains For Generating Antibody Drug Conjugate Biotherapeutics
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.